is it a fair assumption if it is effective in blood clotting cases it stroke victims, it might be equally useful in other scenarios whatever the cause of the blood clot?
Eg AstraZeneca COVID vaccines?
If so, it should attract the attention of global media, there can’t be many current topics more relevant that could garner that kind of coverage…
Ann: Media release - First stroke patient with afamelanotide, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$10.09 |
Change
-0.070(0.69%) |
Mkt cap ! $505.7M | |||
| Open | High | Low | Value | Volume |
| $10.18 | $10.26 | $9.96 | $484.7K | 47.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1627 | $10.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.25 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 07/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |